Nadege Bercovici
Overview
Explore the profile of Nadege Bercovici including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
1308
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Simula L, Fumagalli M, Vimeux L, Rajnpreht I, Icard P, Birsen G, et al.
Nat Commun
. 2024 Mar;
15(1):2203.
PMID: 38467616
The ability of CD8 T cells to infiltrate solid tumors and reach cancer cells is associated with improved patient survival and responses to immunotherapy. Thus, identifying the factors controlling T...
2.
Blampey Q, Bercovici N, Dutertre C, Pic I, Ribeiro J, Andre F, et al.
Brief Bioinform
. 2023 Jul;
24(5).
PMID: 37497716
Cytometry enables precise single-cell phenotyping within heterogeneous populations. These cell types are traditionally annotated via manual gating, but this method lacks reproducibility and sensitivity to batch effect. Also, the most...
3.
Vermare A, Guerin M, Peranzoni E, Bercovici N
Cancers (Basel)
. 2022 Jul;
14(14).
PMID: 35884605
The essential roles endorsed by macrophages and monocytes are well established in response to infections, where they contribute to launching the differentiation of specific T-lymphocytes for long-term protection. This knowledge...
4.
Kantari-Mimoun C, Barrin S, Vimeux L, Haghiri S, Gervais C, Joaquina S, et al.
Cancer Immunol Res
. 2021 Oct;
9(12):1425-1438.
PMID: 34686489
Adoptive transfer of T cells expressing chimeric antigen receptors (CAR) has shown remarkable clinical efficacy against advanced B-cell malignancies but not yet against solid tumors. Here, we used fluorescent imaging...
5.
Guerin M, Regnier F, Thoreau M, Vimeux L, Benard M, Dransart E, et al.
J Immunother Cancer
. 2020 Nov;
8(2).
PMID: 33239415
Background: Tumor relapse constitutes a major challenge for anti-tumoral treatments, including immunotherapies. Indeed, most cancer-related deaths occur during the tumor relapse phase. Methods: We designed a mouse model of tumor...
6.
Alphandery E, Abi Haidar D, Seksek O, Thoreau M, Trautmann A, Bercovici N, et al.
ACS Appl Mater Interfaces
. 2020 Nov;
12(47):53570.
PMID: 33180453
No abstract available.
7.
Guerin M, Finisguerra V, Van den Eynde B, Bercovici N, Trautmann A
Elife
. 2020 Jan;
9.
PMID: 31990272
The goal of this review is to pinpoint the specific features, including the weaknesses, of various tumor models, and to discuss the reasons why treatments that are efficient in murine...
8.
Daher C, Vimeux L, Stoeva R, Peranzoni E, Bismuth G, Wieduwild E, et al.
Cancer Immunol Res
. 2019 Sep;
7(11):1849-1863.
PMID: 31527069
β-Adrenergic receptor (β-AR) signaling exerts protumoral effects by acting directly on tumor cells and angiogenesis. In addition, β-AR expression on immune cells affects their ability to mount antitumor immune responses....
9.
Guerin M, Regnier F, Feuillet V, Vimeux L, Weiss J, Bismuth G, et al.
Nat Commun
. 2019 Sep;
10(1):4131.
PMID: 31511510
Type I interferons (IFN) are being rediscovered as potent anti-tumoral agents. Activation of the STimulator of INterferon Genes (STING) by DMXAA (5,6-dimethylxanthenone-4-acetic acid) can induce strong production of IFNα/β and...
10.
Bercovici N, Guerin M, Trautmann A, Donnadieu E
Front Immunol
. 2019 Jul;
10:1563.
PMID: 31354719
It is well established that tumor-associated macrophages (TAM) found in most advanced tumors have a pro-tumoral role. In this context, TAM limit the activity of tumor-infiltrating lymphocytes (TIL), and a...